CL2024003456A1 - Formas cristalinas de clorhidrato de envudeucitinib, composición farmacéutica, y uso. - Google Patents

Formas cristalinas de clorhidrato de envudeucitinib, composición farmacéutica, y uso.

Info

Publication number
CL2024003456A1
CL2024003456A1 CL2024003456A CL2024003456A CL2024003456A1 CL 2024003456 A1 CL2024003456 A1 CL 2024003456A1 CL 2024003456 A CL2024003456 A CL 2024003456A CL 2024003456 A CL2024003456 A CL 2024003456A CL 2024003456 A1 CL2024003456 A1 CL 2024003456A1
Authority
CL
Chile
Prior art keywords
crystalline forms
hydrochloride
envudeucitinib
pharmaceutical composition
propanoyl
Prior art date
Application number
CL2024003456A
Other languages
English (en)
Spanish (es)
Inventor
By Kolbot
Remarchuk Travis
Original Assignee
Alumis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alumis Inc filed Critical Alumis Inc
Publication of CL2024003456A1 publication Critical patent/CL2024003456A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024003456A 2022-05-13 2024-11-12 Formas cristalinas de clorhidrato de envudeucitinib, composición farmacéutica, y uso. CL2024003456A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263341528P 2022-05-13 2022-05-13
US202263405577P 2022-09-12 2022-09-12

Publications (1)

Publication Number Publication Date
CL2024003456A1 true CL2024003456A1 (es) 2025-04-25

Family

ID=86760338

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024003456A CL2024003456A1 (es) 2022-05-13 2024-11-12 Formas cristalinas de clorhidrato de envudeucitinib, composición farmacéutica, y uso.

Country Status (11)

Country Link
EP (1) EP4522602A1 (enExample)
JP (1) JP2025516683A (enExample)
KR (1) KR20250009492A (enExample)
CN (1) CN119907791A (enExample)
AU (1) AU2023269081A1 (enExample)
CA (1) CA3253365A1 (enExample)
CL (1) CL2024003456A1 (enExample)
IL (1) IL317011A (enExample)
MX (1) MX2024014000A (enExample)
TW (1) TW202409007A (enExample)
WO (1) WO2023220338A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428571A (zh) * 2022-10-10 2024-07-16 美商雅盧米斯公司 Tyk2抑制劑之晶型及其用途
WO2026019902A1 (en) * 2024-07-16 2026-01-22 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250048T1 (hr) * 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba

Also Published As

Publication number Publication date
KR20250009492A (ko) 2025-01-17
JP2025516683A (ja) 2025-05-30
CA3253365A1 (en) 2023-11-16
AU2023269081A1 (en) 2024-11-28
CN119907791A (zh) 2025-04-29
TW202409007A (zh) 2024-03-01
WO2023220338A1 (en) 2023-11-16
EP4522602A1 (en) 2025-03-19
MX2024014000A (es) 2025-02-10
IL317011A (en) 2025-01-01

Similar Documents

Publication Publication Date Title
MX2024014000A (es) Formas cristalinas de un inhibidor de tyk2 y usos de estas
FI3302448T3 (fi) Substituoituja heterosyklyylijohdannaisia cdk-inhibiittoreina
RU2458920C2 (ru) Новые соединения
PE20220766A1 (es) Agonistas de receptor de melanocortina-4
PE20191108A1 (es) Inhibidores selectivos de jak1
PE20220569A1 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y metodos de tratamiento con dichos compuestos
BRPI0114870B8 (pt) uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais
AR057753A2 (es) Derivados de quinazolina, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR020065A1 (es) Uso de inhibidores de proteasas de cisteina para la fabricacion de un medicamento y composicion farmaceutica que los comprende
PH12022550271A1 (en) Solid forms of an hpk1 inhibitor
CA2488785A1 (en) Amine compound and use thereof
PE20220016A1 (es) Inhibidores y metodos de uso de kcnt1
MY208983A (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
CA2434937A1 (en) Phenyl derivatives
CA2551529A1 (en) Amide derivative and medicine
DOP2013000169A (es) Compuesto para uso en el tratamiento de la artritis
MX2021010133A (es) Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifl uorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carbox amida monohidratada.
RU2008143703A (ru) ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА
UY39229A (es) Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina
PL4161929T3 (pl) 1-(5-(2-cyjanopirydyn-4-ylo)oksazolo-2-karbonylo)-4-metyloheksahydropirolo[3,4-b]pirolo-5(1h)-karbonitryl jako inhibitor usp30 do zastosowania w leczeniu dysfunkcji mitochondriów, nowotworu i zwłóknienia
DK3986401T3 (da) Peptidomimetikummet (R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4- oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan- 2-yl)-5-guanidinopentanamid til anvendelse i behandlingen af amyotrofisk lateral sklerose
NO20042861L (no) N-(3-butyn-1-yl)-N-hydroksyurea
DE60308337D1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide zur behandlung von ang-ii vermittelt krankheiten
IL304563A (en) The compound n-(benzoyl)-phenylalanine, a pharmaceutical composition containing it, and its use
RU2009148049A (ru) Терапевтическое средство для лечения церебрального инфаркта